Clinical Trial Update: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above [Phase 3]

View source ↗

Summary

Phase 3 study assessing safety and immune response of an RSV vaccine in adults aged 50-59 (including at higher risk for RSV lower respiratory tract disease) com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• Arexvy

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED | Results posted: 2024-05-21